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BACKGROUND: Due to the low specificity of the prostate-specific antigen (PSA) assay and a high false positive
rate, a large number of prostate cancer (PCA) biopsies are performed unnecessarily. Consequently, there is a need
for new biomarkers that can identify PCA at any stage of progression while limiting the number of false positives.
The use of autoantibody signature–developed biomarkers has proven to be an effective method to solve this
problem. RESULTS: Using T7 phage–peptide detection, we identified a panel of eight biomarkers for PCA on a
training set. The estimated receiver-operating characteristic (ROC) curve had an area under the ROC curve of 0.69
when applied to the validation set. Spearman correlations were high, within 0.7 to 0.9, indicating that the
biomarkers have a degree of inter-relatedness. The identified biomarkers play a role in processes such as
androgen response regulation and cellular structural integrity and are proteins that are thought to play a role in
prostate tumorigenesis. CONCLUSIONS: Autoantibodies against PCA can be developed as biomarkers for
detecting PCA. The scores from the algorithm developed here can be used to indicate a relative high or low risk of
PCA, particularly for patients with intermediate (4.0 to 10 ng/ml) PSA levels. Since most commercially available
assays test for PSA or have a PSA component, this novel approach has the potential to improve diagnosis of PCA
using a biologic measure independent of PSA.
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Prostate cancer (PCA) is the second most common cause of cancer-
related death in American men [1]. The advent of prostate-specific
antigen (PSA) screening has led to earlier detection of PCA [2].
However, the impact of PSA screening on cancer-specific mortality is
still unknown pending the results of prospective randomized
screening studies [3–5]. A major limitation of the serum PSA test is
lack of PCA sensitivity and specificity especially in the intermediate
range of PSA detection (4-10 ng/ml) [6,7]. Elevated serum PSA levels
can be detected in patients with nonmalignant conditions such as
benign prostatic hyperplasia or prostatitis [8], leading to a high rate of
false positives. In situ, PSA is highly expressed in both benign
prostatic epithelial and PCA cells, contributing to the poor specificity
of the serum PSA test, which has been reported to be only 20% at a
sensitivity of 80% [9]. Due to this high rate of false positives, there
has been a dramatic increase in the number of unnecessary prostate
needle biopsies performed [10]. Furthermore, a recent study suggests
lowering the threshold level of PSA needed for recommending
prostate biopsy from 4.1 to 2.6 ng/ml to correct for verification bias
and improve the clinical value of the PSA test [11]. Lowering thethreshold will lead to a further increase in the number of prostate
biopsies performed. To reduce the number of unnecessary prostate
biopsies, development of additional serum and tissue biomarkers to
supplement PSA is needed.
Efforts toward the development of screening tests for PCA have
generally depended on single biomarker molecules, primarily PSA, as
well as PCA3 [12]. Current technologies have been disappointing and
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to apply to clinical practice for detection of early-stage PCA [13]. Like
other cancers, PCA develops in the background of diverse genetic and
environmental factors [14]. Multiple complex molecular events
characterize PCA initiation, unregulated growth, invasion, and
metastasis [14]. Distinct sets of genes and proteins dictate progression
from precursor lesion to localized disease and finally to metastatic
disease. Biomarkers that detect PCA in any of these stages of
progression would be ideal.
A potential approach to develop biomarkers that detect PCA in any
stage of progression is to take advantage of the immune system. The
hypothesis that there is an immune response to cancer in humans has
been demonstrated by the identification of autoantibodies against a
number of intracellular antigens in patients with various tumor types
[15–18]. This phenomenon is known as the humoral response and
the detection of such autoantibodies has been shown to have great
diagnostic and prognostic value in the detection of cancer and the
ability to predict the course of the disease [15–19]. For example, it has
been shown that somatic alterations in the p53 gene elicit a humoral
response in 30% to 40% of affected patients [20]. The detection of
anti-p53 antibodies can predate the diagnosis of the cancer. In other
studies, 60% of patients with lung adenocarcinoma exhibited a
humoral response to glycosylated annexins I and/or II, whereas none
of the noncancerous standards exhibited such a response [19]. There
are now a substantial number of examples demonstrating this
humoral response to patient sera [15–21]. In addition, it has been
shown that the majority of antigens from tumor cells that elicit this
response are not just products of mutated genes. These proteins are
often differentiation antigens or other proteins over-expressed in
cancer [16].
Using T7 phage with epitope inserts, autoantibodies against
peptides derived from PCA tissue have been previously demonstrated
to have utility in diagnosing PCA [22]. The original work of Wang
et al. identified a panel of 22 autoantibody biomarkers that
successfully diagnosed PCA [22]. In the current study, additional
biomarkers were screened and a unique algorithm was developed to
discern between healthy and diseased men irrespective of PSA levels.
The final algorithm incorporated eight biomarkers.
Results
Using T7 phage–peptide display libraries developed previously [22],
we evaluated the relative signal of 62 peptides compared with the
background. The 62 peptides were obtained by screening T7 phage–
peptide display libraries against 96 discreet samples (48 biopsy
positive and 48 clinically negative) on a Luminex platform. ThoseTable 1. Estimated Biomarker Parameters
Analysis of Maximum Likelihood Estimates
Parameter DF * Estimate Standard Error Wald Chi-Square Pr N Chi-Square
Intercept 1 −1.3552 0.2056 43.4638 b0.0001
X3C3_T7 1 −0.00077 0.000394 3.8104 0.0509
X36C4_T7 1 −0.00107 0.000610 3.0517 0.0807
X7A9_T7 1 0.00461 0.000778 35.0869 b0.0001
X5D11_T7 1 −0.00075 0.000399 3.5543 0.0594
X12B2_T7 1 0.00153 0.000285 28.7814 b0.0001
X1B4A_T7 1 0.000686 0.000321 4.5776 0.0324
X3D11_T7 1 −0.00089 0.000350 6.4960 0.0108
X5F8_T7 1 −0.00454 0.000995 20.7982 b0.0001
A logistic regression model was fit in which a linear combination of the biomarkers is used to predict
the probability of a given sample being cancer. * Degrees of Freedom.samples that had elevated signals were selected. Further screening was
done against 300 serum samples, and criteria of relative signal above
background (N1.5), distribution of signal in cancer-positive samples,
and strength of signal (N300 RFI) were used to further reduce the
biomarker pool. This process narrowed down the peptides to a group
of 18 putative biomarkers. Using the training data (519 samples), a
logistic regression model based on eight biomarkers was identified.
The specific biomarkers included in the final model and their
estimated parameter coefficients in the logistic regression model are
shown in Table 1. A significance test of whether each parameter is
significantly different from 0 is also included.
The biomarker parameters can be combined into a single score
called the “linear predictor,” which can be used to calculate the
sensitivity and specificity of the algorithm (Table 2). Given the case-
control nature of this study, in which approximately 50% of the
samples were known to be from PCA patients, the usual estimates of
positive and negative predictive values (PPV and NPV) would need to
be adjusted if this biomarker is applied in a population of men in
which the prevalence of PCA is not 50%.
The estimated receiver-operating characteristic (ROC) curve from
an independent validation set (259 samples) is given in Figure 1 and
compared to the ROC for each individual biomarker included in the
algorithm. The estimated area under the ROC curve (AUC) with
95% confidence interval for this model is 0.69 (0.62, 0.75) when
applied to the validation set. When applied to the same data on which
the model was built (training set), the estimated AUC was 0.74. Total
PSA measurements of samples in other studies within the 2.5 to
20 ng/ml level can have a range of ROC values of 0.54 to 0.67
depending on the cohort of patients being analyzed [37].
The validation process fully complies with the recommendations of
the 2012 report from the Institute of Medicine Committee on
Omics-Based Predictive Tests, “Evolution of Translational Omics:
Lessons Learned and Path Forward” (National Academy Press,
Washington, DC) [23]. The assay and the classifier algorithm were
“locked down” in advance of the validation analysis using entirely
independent samples. The performance of the algorithm on the
independent validation set is much improved over that of a PSA test.
At the balance point of the ROC, the assay displays a sensitivity of
0.65 and a specificity of 0.65. Spearman correlations (the same
interpretation as Pearson’s but rank based to detect nonlinear
relationships) were calculated for each pair of biomarkers. These were
remarkably high for the unnormalized biomarkers with most in the
range of 0.7 to 0.9. This indicates that there is some interdependence
of the biomarkers, in that the markers do not function as stand-alone
markers, but instead they rely and depend on each other to perform.
Investigating the biologic function of each biomarker and seeing whatTable 2. Estimated Diagnostic Accuracy Parameters for a Range of Positivity Thresholds
Corresponding to Sensitivity Values from 10% to 90%
Sensitivity Specificity PPV * NPV *
0.103 0.965 0.389 0.830
0.205 0.912 0.338 0.839
0.301 0.894 0.384 0.854
0.404 0.832 0.345 0.864
0.500 0.788 0.341 0.878
0.603 0.690 0.299 0.888
0.705 0.593 0.276 0.902
0.801 0.451 0.243 0.912
0.904 0.248 0.209 0.922
* PPV and NPV were adjusted to correspond to a population with an 18% cancer prevalence.
Figure 1. Nonparametric ROC curve for fitted model from the
training set when applied to the validation set and compared to the
individual ROCs for each biomarker included in the algorithm.
Table 4. AUC Values Predicted at Various PSA Levels
Included PSA Level AUC
PSA N 4 0.69
PSA N 6 0.70
PSA N 8 0.69
PSA N 10 0.71
PSA N 12 0.67
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of this interdependence (Table 3).
Results of the linear regression of the biomarker score on age
showed that the score does tend to increase with age (N = 429).
Rather than using the linear predictor, we used the predicted
probability of cancer (if XB is the linear predictor, then prob(cancer) =
exp(XB)/(1 + (exp(XB)))). On average, this probability of cancer
increased by 0.04 for each 10-year increase in age among controls. An
analysis was completed to discern whether there was any better
discrimination between low and high levels of PSA with the final
algorithm. Since the analysis did not involve any weighting of higher or
lower PSA values, the algorithm did not give any more weight to higher
PSA levels than low (Table 4).Discussion
The current use of PSA-based screening for PCA has led to earlier
detection of PCA [2]. However, a major limitation of the serum PSA
test is a high rate of false positives due to a lack of sensitivity andTable 3. Biomarker Protein Function
Biomarker NCBI Designation
CSNK2A2 NM_001896.2
Centrosomal protein 164 kDa (minus strand) NM_014956.4
NK3 homeobox 1 NM_033625.2
Aurora kinase interacting protein 1 NM_001127230.1
5′-UTR BMI1 BC011652.2
ARF6 NM_001663.3
Chromosome 3′ UTR region Ropporin/RhoEGF NT_005612.16
Desmocollin 3 NW_004078095.1specificity in the intermediate range of PSA detection (4-10 ng/ml)
[7]. This high rate of false positives results in a large number of
unnecessary prostate biopsies [10]. Moreover, biopsies can sometimes
miss detecting the presence of PCA, even when PSA levels are high [7].
The recent development of autoantibody biomarkers has proven to
be a useful diagnostic in the detection of cancer [15–22]. Through the
use of iterative biopanning and phage-protein microarrays, Wang
et al. has developed an assay whereby multiple autoantibody
biomarkers can be used to screen for PCA [22]. The goal of the
study in this paper was to develop an algorithm to discern healthy
from diseased individuals independent of PSA, building upon the
previous work. Different cohorts of men were used to develop the
algorithm than were used in previous publications. These cohorts
were selected since it has been documented that 40% of men aged 40
to 50 can have undiagnosed, asymptomatic PCA [35]. The incidence
increases by 10% for each subsequent decade. The two arms of the
study were therefore composed of biopsy-positive males (diseased)
and low-PSA, non-PCA family or personal history men under the age
of 40 (clinically healthy). Because older men can have undiagnosed
PCA, the lower aged men were used to decrease the possibility of
having samples that were equivocal for PCA and to increase the
accuracy and utility of the biomarkers selected and the algorithm
developed. Additionally, the study groups did not use PSA values as a
gold standard. Instead, positive biopsy was used as the gold standard
for diseased state. Through iterative biopanning, we narrowed down a
field of 62 peptides to a group of 18 putative biomarkers. These 18
biomarkers were screened and validated using T7 phage display,
resulting in eight PCA biomarkers that were ultimately selected for
the diagnostic algorithm.
The statistical analysis demonstrated that the biomarkers did have a
degree of relatedness. These biomarkers can be classified into two
main biochemical areas: androgen response regulation and cellular
structural integrity, with one additional marker potentially function-
ing to bridge the gap between the two areas. PCA is highly dependent
on androgens for development and progression. Indeed, in many
cases, one of the first lines of treatment is androgen ablation [24].
Specifically, in the androgen response, there are markers related to B
lymphoma Mo-MLV insertion region 1 homolog (BMI1), which is
upregulated in PCA [25]. The markers NKX3.1 and AURKIAP areProtein Function
Serine/threonine kinase involved in regulating cell cycle and cellular division
Spindle pole integrity at centrosome
Regulates androgen response genes (BMI1)
Regulates androgen response genes (TWIST1)
Androgen response gene
Regulates actin cytoskeleton remodeling; vesicle shedding by tumor cells
Ciliary movement in spermatozoa through dynein regulation
Cellular adhesion
Table 5. Demographics and Sample Sources
PCA Samples Healthy Samples
Training Validation Training Validation
n 268 146 251 113
Average age 63 63 32 34
Average PSA 6.5 6.4 b0.2 b0.2
Average Gleason 7 7 N/A N/A
Race, n (%)
Black 24 (9) 10 (7) 117 (47) 55 (49)
Caucasian 164 (61) 102 (70) 60 (24) 25 (22)
Hispanic 0 0 57 (23) 28 (25)
Other/unknown 80 (30) 34 (23) 17 (7) 5 (4)
Source, n (%)
Bioreclamation 24 (9) 13 (9) 251 (100) 113 (100)
Johns Hopkins 75 (28) 37 (25) 0 0
University of Michigan 169 (63) 96 (66) 0 0
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and TWIST1) and the down-regulation/loss of these proteins'
function is another hallmark of PCA progression [25–27]. Presum-
ably, the early immune response is also a factor that causes the
sequestration of some proteins during early tumorigenesis and allows
for the progression of cancer to occur.
Changes in cellular structure and scaffolding are also a key in any
cancer’s progression. Interestingly, four other markers are related to
centrosomal, cytoskeletal regulation and mobility and cellular
adhesion [28–30]. CEP164 was found to be essential for spindle
pole integrity at the microtubular anchors of the centrosome.
Disruption of the protein leads to chromosomal aberrations seen in
tumor cells [28]. ADP-ribosylation factor 6 (ARF6), which regulates
actin cytoskeleton remodeling and is active in vesicle shedding by
tumor cells [30], is also associated with cytoskeletal proteins.
Ropporin is most closely related to ciliary movement in spermatozoa
through dynein regulation, but it has also been found to be a target for
multiple myeloma immunotherapy, suggesting an active role in some
cancer progressions [31]. Desmocollin 3 is involved with cellular
adhesion, and dysregulation has been recognized in tumorigenesis as
well [32,33]. The final marker of the panel, casein kinase 2, alpha prime
polypeptide (CSNK2A2), has long been recognized as an all-purpose
messenger-independent protein serine/threonine kinase [34]. This
protein has been implicated in PCA progression and a variety of cellular
functions ranging from cellular signaling for numerous protein kinases
to regulating cell cycle and cellular division. This marker appears to
bridge the gap between the other two marker sets.
This panel of biomarkers incorporates many proteins that are either
upregulated or altered early on in cancer progression. Additionally,
this panel incorporates proteins from different pathways that all
promote tumorigenesis. The varieties of pathways in which these
proteins are involved strengthen the ability of this assay to detect the
heterogeneity of PCA progression. The early immune response allows
for the detection of these changes at an earlier time point in the
progression of the cancer. There is a gradual rise in the biomarker
levels as age increases in the negative controls. As previously noted,
there is an increase in undiagnosed PCA in men as they age, with a
10% increase with each decade [35]. It is estimated that by age 30,
30% of the male population has prostatic cancer foci within their
prostate. This estimate keeps rising with an 80-year-old man having
an 85% probability of having prostatic cancer foci. The gradual rise in
the biomarkers among the negatives could be a reflection of the
underlying undiagnosed PCA among these men.Conclusion
The scores from the algorithm developed here can be used to indicate
a relative high or low risk of PCA, particularly for patients with
intermediate PSA levels. Most other current commercial assays are
based in some way on PSA. Since this novel autoantibody technology
measures different biologic parameters than PSA, it may provide
additional useful information for physicians involved in the
management of patients at risk for PCA. This assay may also be
effective in addressing the heterogeneity of PCA by measuring
multiple biomarkers that are all known to be PCA-related. Further
studies will have to be done to investigate how the autoantibody
biomarker levels might change over time or if they may be different
before or after a biopsy.
Methods
Patient Samples
The patient cohorts (obtained from the University of Michigan,
Johns Hopkins University, and Bioreclamation; Table 5) were
composed of two arms: 414 men aged 40 to 70 with PSA between 2.5
and 20 ng/ml diagnosed with PCA and 346 men aged 25 to 40 with
PSA b 1.0 ng/ml who were self-reported to be cancer-free and had no
familial PCA history. Young men were selected as the negative cohort
based on concerns that men aged 40 to 70 could potentially have
undiagnosed PCA without elevated PSA [35,36]. These cohorts were
selected since it has been documented that 40% of men aged 40 to 50
can have undiagnosed, asymptomatic PCA. The incidence increases
by 10% for each subsequent decade. The two arms of the study were
therefore composed of biopsy-positive males (diseased) and low-PSA,
non-PCA family or personal history men under the age of 40
(clinically healthy). Because older men can have undiagnosed PCA,
the lower aged men were used to decrease the possibility of having
samples that were equivocal for PCA and to increase the accuracy and
utility of the biomarkers selected and the algorithm developed.Biomarker Identification
Phage libraries that had been developed by iterative biopanning
were used for further screening [22]. A total of 62 biomarkers was
evaluated for relative signal compared to background, and the marker
number was reduced to 18 where the strongest signal-to-noise ratio
over multiple samples was seen. The 18 biomarkers were attached to
Luminex MagPlex beads and tested against training (N = 519, PCA =
268, Healthy = 251) and validation (N = 259, PCA = 146, Healthy =
110 Autoantibody Prostate Biomarker Signature Schipper et al. Translational Oncology Vol. 8, No. 2, 2015113) cohorts. Retrospective samples for these cohorts were obtained
from three different sources (the University of Michigan, Johns
Hopkins University, and Bioreclamation). The analyte tested,
immunoglobulin, is very robust and not prone to degradation with
a simple freeze-thaw cycle. Carboxyl chemistry was used to bind the
phage to the beads, according to the product protocol (Luminex).
Samples were tested in triplicate with high and low serum controls
included on each plate and high and low calibrator beads included in
every sample. The triplicates were averaged to obtain a single value for
each sample. The training cohort was tested with 18 biomarkers to
discern healthy from diseased patients. Logistic regression analysis
determined the optimal panel to be a total of eight biomarkers. The
eight biomarker panel was then used on a separate and distinct
validation patient cohort to assess performance characteristics of the
diagnostic algorithm. The biomarkers consist of T7 phage with
cDNA inserts that correspond to the following proteins/DNA
regions: ARF6, NK3 homeobox 1, Aurora kinase interacting protein
1, CSNK2A2, 5′-UTR-BMI1, centrosomal protein 164 kDa, 3′-
UTR-Ropporin, and Desmocollin. Table 3 summarizes the protein
function and lists the National Center for Biotechnology Information
(NCBI) designation for each biomarker. Biomarker identities were
confirmed by sequencing at the University of Michigan Sequencing
Core with Applied Biosystems DNA Sequencers (Model 3730 XL
sequencer).
Statistical Analysis
Samples were randomly divided into a training set (2/3, N = 519)
and a validation set (1/3, N = 259). These two sets were checked for
comparability with respect to age, race, and the date each sample was
run. Raw biomarker values were normalized by taking the ratio or
absolute difference from T7or BSA. Logistic regression models were
used to model the probability of a sample being cancer as a function of
the potential biomarkers. ROC curves, based on fitted multivariate
logistic regression models, were also generated to show the relation
between sensitivity and specificity for the range of possible cut points.
To determine the optimal number of biomarkers to include in the
final model, we used the following process. For each number of
biomarkers N = 1 to 18 and each normalization method (a total of five
including unnormalized), the best fitting model withN biomarkers was
calculated along with an estimate of the AUC from leave-one-out cross-
validation. No interactions were considered. Although the cross-
validated estimates of AUC were similar for models with six to nine
biomarkers, the numerically highest cross-validated estimate of AUC
was obtained with eight biomarkers using the T7 difference
normalization method. Thus, the final model selected for validation
was obtained as the best fitting model (on the training data) containing
eight biomarkers using the T7 difference normalization.
A biomarker signature was defined as the linear combination of the
eight selected biomarkers each multiplied by their parameter
coefficient from the fitted logistic regression model. The value of
this signature was calculated for patients in the validation set, and a
logistic regression model was used to test its statistical significance.
Sensitivity and specificity associated with this signature, when applied
to the validation set, were calculated at various possible cut points.
The nonparametric estimate of the AUC was also calculated from the
validation set. Prevalence-adjusted PPV and NPV were calculated at
various possible positivity thresholds using the estimated sensitivity
and specificity and an assumed prevalence of cancer equal to 18%
[35]. All analyses were performed using SAS V9.3 (Cary, NC).Acknowledgements
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